Erytech Pharma | Income Statement
Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
261.20
250.20
288.00
427.00
530.00
797
Gross Income
261.20
250.20
288.00
427.00
530.00
797
SG&A Expense
8,290.70
10,230.30
18,143.00
26,247.00
33,724.00
47,271
EBIT
8,915.20
10,974.10
18,431.00
-
34,254.00
48,068
Unusual Expense
212.20
-
81.00
-
-
1,254
Non Operating Income/Expense
452.60
642.90
818.00
339.00
312.00
4,082
Interest Expense
879.80
73.40
64.00
75.00
3,183.00
28
Pretax Income
9,551.40
10,403.90
17,235.00
25,402.00
36,720.00
42,597
Income Tax
1,406.70
1,543.80
2,222.00
3,390.00
3,190.00
4,373
Consolidated Net Income
8,144.70
8,860.00
15,013.00
22,012.00
33,530.00
38,224
Net Income
8,144.70
8,860.00
15,013.00
22,012.00
33,530.00
38,224
Net Income After Extraordinaries
8,144.70
8,860.00
15,013.00
22,012.00
33,530.00
38,224
Net Income Available to Common
8,144.70
8,860.00
15,013.00
22,012.00
33,530.00
38,224
EPS (Basic)
1.74
1.51
2.16
2.76
2.95
2.13
Basic Shares Outstanding
4,686.20
5,874.80
6,957.70
7,983.60
11,370.60
17,937.50
EPS (Diluted)
1.74
1.51
2.16
2.76
2.95
2.13
Diluted Shares Outstanding
4,686.20
5,874.80
6,957.70
7,983.60
11,370.60
17,937.50
EBITDA
8,654.00
10,723.80
18,143.00
25,784.00
33,724.00
47,271
Other Operating Expense
363.40
493.50
-
463.00
-
-
Non-Operating Interest Income
3.20
0.60
523.00
545.00
405.00
163
About Erytech Pharma
View Profile
